<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00267969</url>
  </required_header>
  <id_info>
    <org_study_id>CR006328</org_study_id>
    <secondary_id>C0743T08</secondary_id>
    <secondary_id>2005-003529-15</secondary_id>
    <nct_id>NCT00267969</nct_id>
    <nct_alias>NCT01585714</nct_alias>
  </id_info>
  <brief_title>A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis</brief_title>
  <acronym>PHOENIX1</acronym>
  <official_title>A Phase 3, Multicenter, Randomized, Double-blind, Placebo Controlled Trial Evaluating the Efficacy and Safety of Ustekinumab (CNTO 1275) in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centocor Research &amp; Development, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centocor Research &amp; Development, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the effectiveness and safety of ustekinumab
      (CNTO 1275) in the treatment of patients with moderate to severe plaque psoriasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized (patients are assigned to different treatments based on chance), double
      blind (neither the patient nor the physician knows whether medication or placebo [an inactive
      substance that is compared with a medication to test whether the medication has a real effect
      in a clinical study] is being taken, or at what dosage), parallel-group (each group of
      patients are treated at the same time), multicenter study to determine the effectiveness and
      safety of two different doses of ustekinumab administered subcutaneously (under the skin) as
      compared with placebo in patients with moderate to severe plaque-type psoriasis (the most
      common type of psoriasis). 766 patients will be randomized to Group 1 (ustekinumab 45 mg),
      Group 2 (ustekinumab 90 mg) and Group 3 (placebo) at Week 0. The study was designed to
      evaluate the effectiveness and safety of 2 dose regimens of ustekinumab: (1) 45 mg at Weeks 0
      and 4 followed by 45 mg every 12 weeks maintenance therapy (treatment designed to help the
      original primary treatment succeed) and (2) 90 mg at Weeks 0 and 4 followed by 90 mg every 12
      weeks maintenance therapy. The study will consist of 4 periods: (1) Placebo-controlled
      portion of study [Week 0 to Week 12] during which the safety and effectiveness of 2 doses
      (45mg and 90mg) of ustekinumab will be compared to placebo; (2) Placebo crossover and active
      treatment portion of study [Week 12 to Week 40] during which patients randomized to receive
      placebo at Week 0 will crossover to receive ustekinumab, and all patients will receive active
      treatment; (3) Randomized withdrawal portion of study [beginning at Week 40] during which
      patients who received ustekinumab [45mg or 90mg every 12 weeks] at Week 0 and are responding
      to it, will be randomized either to placebo or continued maintenance therapy with
      ustekinumab; and (4) Long-term extension [from Week 52 to Week 264 (ie, 5 years)] period
      during which the safety and effectiveness of ustekinumab long-term use will be evaluated in
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Psoriasis Area-and-severity Index (PASI) 75% Improvement From Baseline at Week 12.</measure>
    <time_frame>Week 12</time_frame>
    <description>The number of participants achieving at least 75% improvement from baseline in Psoriasis Area and Severity Index (PASI) (0 [best] - 72 [worst]) at Week 12. This is a test of how bad a person's psoriasis is. The combination of redness, scaling, and thickness, as well as overall body involvement determine the PASI score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Achieved a Physician Global Assessment (PGA) Score of Cleared (0) or Minimal (1) at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The PGA is used to determine the participant's psoriasis lesions overall at a given time point. Overall lesions will be graded as : (0) = cleared, (1) = minimal, (2) = mild, (3) = moderate, (4) = marked, and (5) = severe for induration, erythema, and scaling. The sum of the 3 scales will be divided by 3 to obtain a final PGA score ranging from 0 [best] to 5 [worst].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 12</measure>
    <time_frame>Baseline (Week 0), Week 12</time_frame>
    <description>Change from baseline in Dermatology Life Quality Index (DLQI) from baseline at Week 12. This DLQI is a 10-item questionnaire, that in addition to evaluating overall quality of life, can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. Scores range from 0 (no impairment in quality of life) to 30 (most impairment in quality of life).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psoriasis Area and Severity Index (PASI) 75 Responders at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>The number of participants achieving at least 75% improvement from baseline in Psoriasis Area and Severity Index (PASI) (0 [best] - 72 [worst]) at Week 52 in participants randomly assigned to a treatment group at Week 40. This is a test of how bad a person's psoriasis is. The combination of redness, scaling, and thickness, as well as overall body involvement determine the PASI score.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">766</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>ustekinumab 45 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received ustekinumab 45 mg at Weeks 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 40, patients who achieved PASI 75 at both Week 28 and Week 40 were re-randomized to withdraw from therapy (placebo) or continue 45 mg every 12 week maintenance therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ustekinumab 90 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received ustekinumab 90 mg at Week 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 40, patients who achieved PASI 75 at both Week 28 and Week 40 were re-randomized to withdraw from therapy (placebo) or continue 90 mg every 12 week maintenance therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients received placebo at Weeks 0 and 4. At Weeks 12 and 16, placebo crossed over to receive ustekinumab 45 mg or 90 mg. Treatments after Week 16 were dependent on clinical response.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ustekinumab</intervention_name>
    <description>Type = exact number, Form = solution for injection, Number = 45 and 90, Unit = mg, Route = subcutaneous (SC) administered at Weeks 0, 4 and 16. Both treatments (45 mg and 90 mg) administered every 12 weeks after Week 16 depending on clinical response.</description>
    <arm_group_label>ustekinumab 45 mg</arm_group_label>
    <arm_group_label>ustekinumab 90 mg</arm_group_label>
    <other_name>CNTO 1275</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Form = solution for injection, route = SC administered at Weeks 0 and 4. At Weeks 12 and 16, placebo will be crossed over to receive ustekinumab 45 mg or 90 mg.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with plaque-type psoriasis diagnosed at least 6 months prior and covering at
             least 10% of total body surface areas

          -  Have psoriasis area-and-severity index score of &gt;=12

          -  Patients who are considered by treating dermatologist to be a candidate for
             phototherapy or systemic treatment of psoriasis

          -  Have no history of latent or active TB

        Exclusion Criteria:

          -  Currently have nonplaque forms of psoriasis or drug-induced psoriasis

          -  Have any therapeutic agent targeted at reducing IL-12 or IL-23

          -  Have had a BCG vaccination within the previous 12 months

          -  Have a history of chronic or recurrent infectious disease or who have or have had a
             serious infection requiring hospitalization or intravenous antibiotics within the
             previous 2 months

          -  Have or ever have had a nontuberculous mycobacterial infection or opportunistic
             infection

          -  Patients known to be infected with human immunodeficiency virus, hepatitis B, or
             hepatitis C

          -  Have current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic,
             hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, cerebral,
             or psychiatric disease

          -  Patients with a malignancy or who have a history of malignancy (with the exception of
             certain skin cancers and pre-invasive cervical cancer)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Centocor Research &amp; Development, Inc. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Centocor Research &amp; Development, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alpharetta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>East Windsor</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lake Oswego</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goodlettsville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St-John'S</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Bay</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2005</study_first_submitted>
  <study_first_submitted_qc>December 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2005</study_first_posted>
  <results_first_submitted>October 23, 2009</results_first_submitted>
  <results_first_submitted_qc>July 23, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 24, 2012</results_first_posted>
  <last_update_submitted>June 10, 2013</last_update_submitted>
  <last_update_submitted_qc>June 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ustekinumab</keyword>
  <keyword>CNTO1275</keyword>
  <keyword>Plaque type Psoriasis</keyword>
  <keyword>Interleukin-23</keyword>
  <keyword>IL-23</keyword>
  <keyword>Psoriasis</keyword>
  <keyword>Interleukin 12</keyword>
  <keyword>IL-12</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ustekinumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>In this study, 766 patients were randomized in North America and Europe to receive either placebo or ustekinumab (CNTO 1275).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo (CP)</title>
          <description>Controlled period (Week 0-12) - Placebo group</description>
        </group>
        <group group_id="P2">
          <title>Ustekinumab 45 mg (CP)</title>
          <description>Controlled period (Week 0-12) - Ustekinumab 45 mg group</description>
        </group>
        <group group_id="P3">
          <title>Ustekinumab 90 mg (CP)</title>
          <description>Controlled period (Week 0-12) - Ustekinumab 90 mg group</description>
        </group>
        <group group_id="P4">
          <title>Placebo -&gt; Ustekinumab 45 mg (After CP)</title>
          <description>After Controlled period (Week 12-264) – patients receiving Placebo at Weeks 0 and 4 -&gt; receiving ustekinumab 45 mg every 12 weeks (q12wk) or every 8 weeks (q8wk) from Week 12 to Week 244. Some patients were withdrawn from ustekinumab at Week 40 and re-treated with ustekinumab 45 q12w.</description>
        </group>
        <group group_id="P5">
          <title>Placebo -&gt; Ustekinumab 90 mg (After CP)</title>
          <description>After Controlled period (Week 12-264) – patients receiving Placebo at Weeks 0 and 4 -&gt; receiving ustekinumab 90 mg q12wk or q8wk from Week 12 to Week 244. Some patients were withdrawn from ustekinumab at Week 40 and re-treated with ustekinumab 90 q12w.</description>
        </group>
        <group group_id="P6">
          <title>Ustekinumab 45 mg (After CP)</title>
          <description>After Controlled period (Week 12-264) – patients receiving ustekinumab 45 mg at Weeks 0 and 4 -&gt; receiving ustekinumab 45 mg q12wk or q8wk from Week 16 to Week 244. Some patients were withdrawn from ustekinumab at Week 40 and re-treated with ustekinumab 45 q12w.</description>
        </group>
        <group group_id="P7">
          <title>Ustekinumab 90 mg (After CP)</title>
          <description>After Controlled period (Week 12-264) – patients receiving ustekinumab 90 mg at Weeks 0 and 4 -&gt; receiving ustekinumab 90 mg q12wk or q8wk from Week 16 to Week 244. Some patients were withdrawn from ustekinumab at Week 40 and re-treated with ustekinumab 90 q12w.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Controlled Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="255">Number of patients randomized</participants>
                <participants group_id="P2" count="255">Number of patients randomized</participants>
                <participants group_id="P3" count="256">Number of patients randomized</participants>
                <participants group_id="P4" count="0">&quot;0&quot; in column indicates this reporting group is not relevant to Controlled Period.</participants>
                <participants group_id="P5" count="0">&quot;0&quot; in column indicates this reporting group is not relevant to Controlled Period.</participants>
                <participants group_id="P6" count="0">&quot;0&quot; in column indicates this reporting group is not relevant to Controlled Period.</participants>
                <participants group_id="P7" count="0">&quot;0&quot; in column indicates this reporting group is not relevant to Controlled Period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="243"/>
                <participants group_id="P2" count="254"/>
                <participants group_id="P3" count="245"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but not treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>After Controlled Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">&quot;0&quot; in column indicates this reporting group is not relevant to after Controlled Period.</participants>
                <participants group_id="P2" count="0">&quot;0&quot; in column indicates this reporting group is not relevant to after Controlled Period.</participants>
                <participants group_id="P3" count="0">&quot;0&quot; in column indicates this reporting group is not relevant to after Controlled Period.</participants>
                <participants group_id="P4" count="123"/>
                <participants group_id="P5" count="120"/>
                <participants group_id="P6" count="254"/>
                <participants group_id="P7" count="245"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="87"/>
                <participants group_id="P5" count="85"/>
                <participants group_id="P6" count="172"/>
                <participants group_id="P7" count="173"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="36"/>
                <participants group_id="P5" count="35"/>
                <participants group_id="P6" count="82"/>
                <participants group_id="P7" count="72"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="23"/>
                <participants group_id="P7" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="28"/>
                <participants group_id="P7" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="22"/>
                <participants group_id="P7" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Patients received placebo at Weeks 0 and 4. At Weeks 12 and 16, placebo crossed over to receive ustekinumab 45 mg or 90 mg. Treatments after Week 16 were dependent on clinical response.</description>
        </group>
        <group group_id="B2">
          <title>Ustekinumab 45 mg</title>
          <description>Patients received ustekinumab 45 mg at Weeks 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 40, patients who achieved PASI 75 at both Week 28 and Week 40 were re-randomized to withdraw from therapy (placebo) or continue 45 mg every 12 week maintenance therapy.</description>
        </group>
        <group group_id="B3">
          <title>Ustekinumab 90 mg</title>
          <description>Patients received ustekinumab 90 mg at Week 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 40, patients who achieved PASI 75 at both Week 28 and Week 40 were re-randomized to withdraw from therapy (placebo) or continue 90 mg every 12 week maintenance therapy.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="255"/>
            <count group_id="B2" value="255"/>
            <count group_id="B3" value="256"/>
            <count group_id="B4" value="766"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.8" spread="11.32"/>
                    <measurement group_id="B2" value="44.8" spread="12.48"/>
                    <measurement group_id="B3" value="46.2" spread="11.27"/>
                    <measurement group_id="B4" value="45.3" spread="11.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="183"/>
                    <measurement group_id="B2" value="175"/>
                    <measurement group_id="B3" value="173"/>
                    <measurement group_id="B4" value="531"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Psoriasis Area-and-severity Index (PASI) 75% Improvement From Baseline at Week 12.</title>
        <description>The number of participants achieving at least 75% improvement from baseline in Psoriasis Area and Severity Index (PASI) (0 [best] - 72 [worst]) at Week 12. This is a test of how bad a person's psoriasis is. The combination of redness, scaling, and thickness, as well as overall body involvement determine the PASI score.</description>
        <time_frame>Week 12</time_frame>
        <population>Intent to treat. All patients randomized were included in the analysis according to the assigned treatment groups. Patient is considered a non- responder if the patient has used any pre-specified prohibited medications or discontinued due to lack of efficacy, or an AE of worsening of psoriasis, or had missing data at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients received placebo at Weeks 0 and 4. At Weeks 12 and 16, placebo crossed over to receive ustekinumab 45 mg or 90 mg. Treatments after Week 16 were dependent on clinical response.</description>
          </group>
          <group group_id="O2">
            <title>Ustekinumab 45 mg</title>
            <description>Patients received ustekinumab 45 mg at Weeks 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 40, patients who achieved PASI 75 at both Week 28 and Week 40 were re-randomized to withdraw from therapy (placebo) or continue 45 mg every 12 week maintenance therapy.</description>
          </group>
          <group group_id="O3">
            <title>Ustekinumab 90 mg</title>
            <description>Patients received ustekinumab 90 mg at Week 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 40, patients who achieved PASI 75 at both Week 28 and Week 40 were re-randomized to withdraw from therapy (placebo) or continue 90 mg every 12 week maintenance therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Psoriasis Area-and-severity Index (PASI) 75% Improvement From Baseline at Week 12.</title>
          <description>The number of participants achieving at least 75% improvement from baseline in Psoriasis Area and Severity Index (PASI) (0 [best] - 72 [worst]) at Week 12. This is a test of how bad a person's psoriasis is. The combination of redness, scaling, and thickness, as well as overall body involvement determine the PASI score.</description>
          <population>Intent to treat. All patients randomized were included in the analysis according to the assigned treatment groups. Patient is considered a non- responder if the patient has used any pre-specified prohibited medications or discontinued due to lack of efficacy, or an AE of worsening of psoriasis, or had missing data at Week 12.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="255"/>
                <count group_id="O3" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="171"/>
                    <measurement group_id="O3" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel (CMH) chi square</method>
            <method_desc>Stratified by baseline weight [≤ 90kg vs &gt; 90 kg)].</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: No difference between ustekinumab 90 mg or 45 mg and placebo at an overall significance level of 0.05. Sample Size: With 750 patients (250 in each treatment group), simulation studies were conducted to calculate the power to detect a treatment difference in the primary endpoint between ustekinumab groups and placebo using a CMH test stratified by baseline weight [&lt;=90kg vs &gt; 90 kg). For all the scenarios evaluated, the power is &gt;99% at an overall significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>To control for the multiplicity for the primary endpoint analysis, the Holm’s procedure was used at an overall significance level of 0.05</p_value_desc>
            <method>Cochran-Mantel-Haenszel (CMH) chi square</method>
            <method_desc>Stratified by baseline weight [≤ 90kg vs &gt; 90 kg)].</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Achieved a Physician Global Assessment (PGA) Score of Cleared (0) or Minimal (1) at Week 12</title>
        <description>The PGA is used to determine the participant’s psoriasis lesions overall at a given time point. Overall lesions will be graded as : (0) = cleared, (1) = minimal, (2) = mild, (3) = moderate, (4) = marked, and (5) = severe for induration, erythema, and scaling. The sum of the 3 scales will be divided by 3 to obtain a final PGA score ranging from 0 [best] to 5 [worst].</description>
        <time_frame>Week 12</time_frame>
        <population>Intent to treat. All patients were included in the analysis according to the assigned treatment groups. Patient is considered a non- responder if the patient has used any pre-specified prohibited medications or discontinued due to lack of efficacy, or an AE of worsening of psoriasis, or had missing data at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients received placebo at Weeks 0 and 4. At Weeks 12 and 16, placebo crossed over to receive ustekinumab 45 mg or 90 mg. Treatments after Week 16 were dependent on clinical response.</description>
          </group>
          <group group_id="O2">
            <title>Ustekinumab 45 mg</title>
            <description>Patients received ustekinumab 45 mg at Weeks 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 40, patients who achieved PASI 75 at both Week 28 and Week 40 were re-randomized to withdraw from therapy (placebo) or continue 45 mg every 12 week maintenance therapy.</description>
          </group>
          <group group_id="O3">
            <title>Ustekinumab 90 mg</title>
            <description>Patients received ustekinumab 90 mg at Week 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 40, patients who achieved PASI 75 at both Week 28 and Week 40 were re-randomized to withdraw from therapy (placebo) or continue 90 mg every 12 week maintenance therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Achieved a Physician Global Assessment (PGA) Score of Cleared (0) or Minimal (1) at Week 12</title>
          <description>The PGA is used to determine the participant’s psoriasis lesions overall at a given time point. Overall lesions will be graded as : (0) = cleared, (1) = minimal, (2) = mild, (3) = moderate, (4) = marked, and (5) = severe for induration, erythema, and scaling. The sum of the 3 scales will be divided by 3 to obtain a final PGA score ranging from 0 [best] to 5 [worst].</description>
          <population>Intent to treat. All patients were included in the analysis according to the assigned treatment groups. Patient is considered a non- responder if the patient has used any pre-specified prohibited medications or discontinued due to lack of efficacy, or an AE of worsening of psoriasis, or had missing data at Week 12.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="255"/>
                <count group_id="O3" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="151"/>
                    <measurement group_id="O3" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel(CMH) chi square</method>
            <method_desc>Stratified by baseline weight [≤ 90kg vs &gt; 90 kg)].</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: No difference between ustekinumab 90 mg or 45 mg and placebo at an overall significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>To control the multiplicity for the primary and the secondary endpoint analyses, Holm’s procedure was used but the two comparisons for the primary endpoint and the two comparisons for the 1st second endpoint analyses need to be significant first</p_value_desc>
            <method>Cochran-Mantel-Haenszel (CMH) chi square</method>
            <method_desc>Stratified by baseline weight [≤ 90kg vs &gt; 90 kg)].</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 12</title>
        <description>Change from baseline in Dermatology Life Quality Index (DLQI) from baseline at Week 12. This DLQI is a 10-item questionnaire, that in addition to evaluating overall quality of life, can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. Scores range from 0 (no impairment in quality of life) to 30 (most impairment in quality of life).</description>
        <time_frame>Baseline (Week 0), Week 12</time_frame>
        <population>Patients were included in the analysis according to the assigned treatment groups. Zero change is imputed if the patient has used any pre-specified prohibited medications or discontinued due to lack of efficacy. Other missing data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients received placebo at Weeks 0 and 4. At Weeks 12 and 16, placebo crossed over to receive ustekinumab 45 mg or 90 mg. Treatments after Week 16 were dependent on clinical response.</description>
          </group>
          <group group_id="O2">
            <title>Ustekinumab 45 mg</title>
            <description>Patients received ustekinumab 45 mg at Weeks 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 40, patients who achieved PASI 75 at both Week 28 and Week 40 were re-randomized to withdraw from therapy (placebo) or continue 45 mg every 12 week maintenance therapy.</description>
          </group>
          <group group_id="O3">
            <title>Ustekinumab 90 mg</title>
            <description>Patients received ustekinumab 90 mg at Week 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 40, patients who achieved PASI 75 at both Week 28 and Week 40 were re-randomized to withdraw from therapy (placebo) or continue 90 mg every 12 week maintenance therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 12</title>
          <description>Change from baseline in Dermatology Life Quality Index (DLQI) from baseline at Week 12. This DLQI is a 10-item questionnaire, that in addition to evaluating overall quality of life, can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. Scores range from 0 (no impairment in quality of life) to 30 (most impairment in quality of life).</description>
          <population>Patients were included in the analysis according to the assigned treatment groups. Zero change is imputed if the patient has used any pre-specified prohibited medications or discontinued due to lack of efficacy. Other missing data were not imputed.</population>
          <units>Scores on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="252"/>
                <count group_id="O2" value="254"/>
                <count group_id="O3" value="249"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-3.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="-6.0" lower_limit="-12.0" upper_limit="-3.0"/>
                    <measurement group_id="O3" value="-7.0" lower_limit="-12.0" upper_limit="-4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA on van der Waerden normal scores</method>
            <method_desc>Treatment and patient's baseline weight (≤ 90kg vs &gt; 90 kg) as factors in the model</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: No difference between ustekinumab 90 mg or 45 mg and placebo at an overall significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>To control the multiplicity for the primary and the secondary endpoint analyses, Holm’s procedure was used but the two comparisons for the primary endpoint and the two comparisons for the 1st second endpoint analyses need to be significant first</p_value_desc>
            <method>ANOVA on van der Waerden normal scores</method>
            <method_desc>Treatment and patient's baseline weight (≤ 90kg vs &gt; 90 kg) as factors in the model</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Psoriasis Area and Severity Index (PASI) 75 Responders at Week 52</title>
        <description>The number of participants achieving at least 75% improvement from baseline in Psoriasis Area and Severity Index (PASI) (0 [best] - 72 [worst]) at Week 52 in participants randomly assigned to a treatment group at Week 40. This is a test of how bad a person's psoriasis is. The combination of redness, scaling, and thickness, as well as overall body involvement determine the PASI score.</description>
        <time_frame>Week 52</time_frame>
        <population>Patients were included in the analysis according to the assigned treatment groups. Patient is considered a non- responder if the patient has used any pre-specified prohibited medications or discontinued due to lack of efficacy. Other missing data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Ustekinumab 45 mg Withdrawal Group</title>
            <description>Patients received ustekinumab 45 mg at Weeks 0, 4, 16 and 28.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Ustekinumab 45 mg Every 12 Weeks</title>
            <description>Patients received ustekinumab 45 mg at Weeks 0, 4, 16, 28 and 40.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Ustekinumab 90 mg Withdrawal</title>
            <description>Patients received ustekinumab 90 mg at Weeks 0, 4, 16 and 28.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Ustekinumab 90 mg Every 12 Weeks</title>
            <description>Patients received ustekinumab 90 mg at Weeks 0, 4, 16, 28 and 40.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Withdrawal Combined Group</title>
            <description>Groups 1 and 3 (Withdrawal Combined)</description>
          </group>
          <group group_id="O6">
            <title>Group 6: Combined Ustekinumab Every 12 Weeks</title>
            <description>Groups 2 and 4 (Combined Ustekinumab every 12 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Psoriasis Area and Severity Index (PASI) 75 Responders at Week 52</title>
          <description>The number of participants achieving at least 75% improvement from baseline in Psoriasis Area and Severity Index (PASI) (0 [best] - 72 [worst]) at Week 52 in participants randomly assigned to a treatment group at Week 40. This is a test of how bad a person's psoriasis is. The combination of redness, scaling, and thickness, as well as overall body involvement determine the PASI score.</description>
          <population>Patients were included in the analysis according to the assigned treatment groups. Patient is considered a non- responder if the patient has used any pre-specified prohibited medications or discontinued due to lack of efficacy. Other missing data were not imputed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="159"/>
                <count group_id="O6" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="77"/>
                    <measurement group_id="O5" value="100"/>
                    <measurement group_id="O6" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel (CMH) chi square</method>
            <method_desc>Stratified by baseline weight [≤ 90kg vs &gt; 90 kg)].</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel (CMH) chi square</method>
            <method_desc>Stratified by baseline weight [≤ 90kg vs &gt; 90 kg)].</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: No difference between combined maintenance group and the combined withdrawal group, ustekinumab 90 mg maintenance group and the withdrawal group, ustekinumab 45 mg maintenance group and the withdrawal group at an overall significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>To control the overall multiplicity, the combined groups was tested first and each dose will then be tested; but the primary and the 1st 2 secondary endpoint analyses need to be significant before this endpoint can be tested</p_value_desc>
            <method>Cochran-Mantel-Haenszel (CMH) chi square</method>
            <method_desc>Stratified by baseline weight [≤ 90kg vs &gt; 90 kg)].</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>264 weeks</time_frame>
      <desc>In adverse events reporting: 1 patient not included was randomized in Ustekinumab 90 mg Controlled period (CP) but not treated. 1 patient included in Ustekinumab 45 mg (after CP) and 6 patients included in Ustekinumab 90 mg (after CP) had discontinued study agent during the CP but had follow-up after CP.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo (CP)</title>
          <description>Controlled period (Week 0-12) - Placebo group</description>
        </group>
        <group group_id="E2">
          <title>Ustekinumab 45 mg (CP)</title>
          <description>Controlled period (Week 0-12) - Ustekinumab 45 mg group</description>
        </group>
        <group group_id="E3">
          <title>Ustekinumab 90 mg (CP)</title>
          <description>Controlled period (Week 0-12) - Ustekinumab 90 mg group</description>
        </group>
        <group group_id="E4">
          <title>Placebo -&gt; Ustekinumab 45 mg (After CP)</title>
          <description>After Controlled period (Week 12-264) – patients receiving Placebo at Weeks 0 and 4 -&gt; receiving ustekinumab 45 mg every 12 weeks (q12wk) or every 8 weeks (q8wk) from Week 12 to Week 244. Some patients were withdrawn from ustekinumab at Week 40 and re-treated with ustekinumab 45 q12w.</description>
        </group>
        <group group_id="E5">
          <title>Placebo -&gt; Ustekinumab 90 mg (After CP)</title>
          <description>After Controlled period (Week 12-264) – patients receiving Placebo at Weeks 0 and 4 -&gt; receiving ustekinumab 90 mg q12wk or q8wk from Week 12 to Week 244. Some patients were withdrawn from ustekinumab at Week 40 and re-treated with ustekinumab 90 q12w.</description>
        </group>
        <group group_id="E6">
          <title>Ustekinumab 45 mg (After CP)</title>
          <description>After Controlled period (Week 12-264) – patients receiving ustekinumab 45 mg at Weeks 0 and 4 -&gt; receiving ustekinumab 45 mg q12wk or q8wk from Week 16 to Week 244. Some patients were withdrawn from ustekinumab at Week 40 and re-treated with ustekinumab 45 q12w.</description>
        </group>
        <group group_id="E7">
          <title>Ustekinumab 90 mg (After CP)</title>
          <description>After Controlled period (Week 12-264) – patients receiving ustekinumab 90 mg at Weeks 0 and 4 -&gt; receiving ustekinumab 90 mg q12wk or q8wk from Week 16 to Week 244. Some patients were withdrawn from ustekinumab at Week 40 and re-treated with ustekinumab 90 q12w.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="38" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="33" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Polydactyly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness neurosensory</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Drug withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Chronic hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Asymptomatic HIV infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Endocarditis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Herpes zoster disseminated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Anaesthetic complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Uterine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Chorea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Renal infarct</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="102" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="84" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="110" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="102" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="207" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="207" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="18" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="25" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="29" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="25" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="28" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="27" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="36" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="70" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="75" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="37" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="31" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="34" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="82" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="77" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="14" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="34" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="82" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="77" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="15" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="22" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="17" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="31" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="33" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="27" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="15" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="24" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="17" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="14" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="18" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="123"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="255"/>
                <counts group_id="E7" subjects_affected="30" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Generally, the only disclosure restriction on the PI is that the sponsor has 60 days to review results communications prior to public release and can embargo communications regarding trial results for a period that does not exceed 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The count of patients with any nonserious adverse event (NAE) excludes patients who only had NAE that occured in &lt;=5% of patients. This information may vary from existing approved labeling and publications due to the requirements of this website.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dir. Clinical Research</name_or_title>
      <organization>Centocor Research &amp; Development, Inc.</organization>
      <phone>1-800-457-6399</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

